Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

The Health and Human Services Department is weighing plans to “drastically” cut the federal government’s funding for domestic HIV prevention, ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...